G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 26.2 PLN 4.8% Market Closed
Market Cap: 34.6m PLN
Have any thoughts about
Genomed SA?
Write Note

Genomed SA
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genomed SA
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
G
Genomed SA
WSE:GEN
Accounts Receivables
zł1.7m
CAGR 3-Years
17%
CAGR 5-Years
13%
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Accounts Receivables
zł296k
CAGR 3-Years
-30%
CAGR 5-Years
64%
CAGR 10-Years
-26%
R
Read Gene SA
WSE:RDG
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
U
Urteste SA
WSE:URT
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genomed SA
Glance View

Market Cap
34.6m PLN
Industry
Biotechnology

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

GEN Intrinsic Value
25.37 PLN
Overvaluation 3%
Intrinsic Value
Price
G

See Also

What is Genomed SA's Accounts Receivables?
Accounts Receivables
1.7m PLN

Based on the financial report for Dec 31, 2023, Genomed SA's Accounts Receivables amounts to 1.7m PLN.

What is Genomed SA's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
13%

Over the last year, the Accounts Receivables growth was 33%. The average annual Accounts Receivables growth rates for Genomed SA have been 17% over the past three years , 13% over the past five years .

Back to Top